TP53 and breast carcinoma: Our current study also showed that Src-silenced breast cancer cells with a TP53 mutation, such as MDA-MB-231, Hs578T, and T47D cells, were relatively more sensitive to doxorubicin than that in MCF-7 cells, which have wild-type TP53.